Elena Laakmann1, Volkmar Müller1, Marcus Schmidt2, Isabell Witzel1. 1. Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Gynecology, University Medical Center Mainz, Mainz, Germany.
Abstract
BACKGROUND: The incidence of brain metastases (BM) in breast cancer patients has increased. Many retrospective analyses have shown that first-line treatment with trastuzumab prolongs survival in patients with HER2-positive BM. In contrast, the evidence for other therapies targeting HER2 for patients with BM is rare. METHODS: The aim of this review is to update the reader about current systemic treatment options in patients with HER2-positive metastatic breast cancer with BM who had already received trastuzumab. A literature search was performed in the PubMed database in June 2016. 30 relevant reports concerning the efficacy of trastuzumab emtansine (T-DM1), lapatinib and its combination with other cytotoxic agents, pertuzumab and novel HER2-targeting substances were identified. RESULTS: There is limited but promising evidence for the use of T-DM1 and pertuzumab in the treatment of BM. Up to now, most reported studies used lapatinib as treatment of HER2-positive breast cancer with BM, a treatment with only a modest effect and a high toxicity profile. The combination of lapatinib with cytotoxic agents seems to result in better response rates. CONCLUSION: Further prospective investigations are needed to investigate the efficacy of the established and novel HER2-targeting agents on BM in HER2-positive breast cancer patients.
BACKGROUND: The incidence of brain metastases (BM) in breast cancerpatients has increased. Many retrospective analyses have shown that first-line treatment with trastuzumab prolongs survival in patients with HER2-positive BM. In contrast, the evidence for other therapies targeting HER2 for patients with BM is rare. METHODS: The aim of this review is to update the reader about current systemic treatment options in patients with HER2-positive metastatic breast cancer with BM who had already received trastuzumab. A literature search was performed in the PubMed database in June 2016. 30 relevant reports concerning the efficacy of trastuzumab emtansine (T-DM1), lapatinib and its combination with other cytotoxic agents, pertuzumab and novel HER2-targeting substances were identified. RESULTS: There is limited but promising evidence for the use of T-DM1 and pertuzumab in the treatment of BM. Up to now, most reported studies used lapatinib as treatment of HER2-positive breast cancer with BM, a treatment with only a modest effect and a high toxicity profile. The combination of lapatinib with cytotoxic agents seems to result in better response rates. CONCLUSION: Further prospective investigations are needed to investigate the efficacy of the established and novel HER2-targeting agents on BM in HER2-positive breast cancerpatients.
Entities:
Keywords:
Brain metastases; Breast cancer; HER2; Therapy resistance
Authors: G Metro; J Foglietta; M Russillo; L Stocchi; A Vidiri; D Giannarelli; L Crinò; P Papaldo; M Mottolese; F Cognetti; A Fabi; S Gori Journal: Ann Oncol Date: 2010-08-19 Impact factor: 32.976
Authors: Edith A Perez; Ahmad Awada; Joyce O'Shaughnessy; Hope S Rugo; Chris Twelves; Seock-Ah Im; Patricia Gómez-Pardo; Lee S Schwartzberg; Veronique Diéras; Denise A Yardley; David A Potter; Audrey Mailliez; Alvaro Moreno-Aspitia; Jin-Seok Ahn; Carol Zhao; Ute Hoch; Mary Tagliaferri; Alison L Hannah; Javier Cortes Journal: Lancet Oncol Date: 2015-10-22 Impact factor: 41.316
Authors: Nancy U Lin; Rachel A Freedman; Naren Ramakrishna; Jerry Younger; Anna Maria Storniolo; Jennifer R Bellon; Steven E Come; Rebecca S Gelman; Gordon J Harris; Mark A Henderson; Shannon M Macdonald; Anand Mahadevan; Emily Eisenberg; Jennifer A Ligibel; Erica L Mayer; Beverly Moy; April F Eichler; Eric P Winer Journal: Breast Cancer Res Treat Date: 2013-11-07 Impact factor: 4.872
Authors: Nancy U Lin; Lisa A Carey; Minetta C Liu; Jerry Younger; Steven E Come; Matthew Ewend; Gordon J Harris; Elizabeth Bullitt; Annick D Van den Abbeele; John W Henson; Xiaochun Li; Rebecca Gelman; Harold J Burstein; Elizabeth Kasparian; David G Kirsch; Ann Crawford; Fred Hochberg; Eric P Winer Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: Julie A Carlson; Zohra Nooruddin; Chad Rusthoven; Anthony Elias; Virginia F Borges; Jennifer R Diamond; Brian Kavanagh; Peter Kabos Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: R Bartsch; A Berghoff; U Pluschnig; Z Bago-Horvath; P Dubsky; A Rottenfusser; C DeVries; M Rudas; F Fitzal; K Dieckmann; R M Mader; M Gnant; C C Zielinski; G G Steger Journal: Br J Cancer Date: 2011-11-29 Impact factor: 7.640
Authors: Isabell Witzel; Leticia Oliveira-Ferrer; Klaus Pantel; Volkmar Müller; Harriet Wikman Journal: Breast Cancer Res Date: 2016-01-19 Impact factor: 6.466
Authors: S Sutherland; S Ashley; D Miles; S Chan; A Wardley; N Davidson; R Bhatti; M Shehata; H Nouras; T Camburn; S R D Johnston Journal: Br J Cancer Date: 2010-02-23 Impact factor: 7.640
Authors: Virginia F Borges; Cristiano Ferrario; Nathalie Aucoin; Carla Falkson; Qamar Khan; Ian Krop; Stephen Welch; Alison Conlin; Jorge Chaves; Philippe L Bedard; Marc Chamberlain; Todd Gray; Alex Vo; Erika Hamilton Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Amaia Eleonora Maennling; Mehmet Kemal Tur; Marcus Niebert; Torsten Klockenbring; Felix Zeppernick; Stefan Gattenlöhner; Ivo Meinhold-Heerlein; Ahmad Fawzi Hussain Journal: Cancers (Basel) Date: 2019-11-20 Impact factor: 6.639